CA Stock MarketDetailed Quotes
PRN Profound Medical Corp
- 12.360
- -0.210-1.67%
15min DelayMarket Closed Aug 30 16:00 ET
302.60MMarket Cap-7405P/E (TTM)
12.680High12.160Low2.41KVolume12.600Open12.570Pre Close29.75KTurnover16.00052wk High0.01%Turnover Ratio24.48MShares9.55052wk Low-1.669EPS TTM274.19MFloat Cap36.730Historical HighLossP/E (Static)22.18MShs Float4.210Historical Low-1.79EPS LYR4.14%Amplitude--Dividend TTM5.72P/B1Lot Size--Div YieldTTM
Profound Medical Corp Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 39.39%2.23M | 2.69%1.91M | 7.75%7.2M | 59.82%2.01M | -15.09%1.73M | -20.89%1.6M | 36.36%1.86M | -2.79%6.68M | 25.95%1.26M | -19.79%2.04M |
| Operating revenue | 39.39%2.23M | 2.69%1.91M | 7.75%7.2M | 59.82%2.01M | -15.09%1.73M | -20.89%1.6M | 36.36%1.86M | -2.79%6.68M | 25.95%1.26M | -19.79%2.04M |
| Cost of revenue | 44.02%795K | -0.93%641K | -23.03%2.82M | 36.10%950K | -29.31%668K | -49.31%552K | -30.28%647K | -6.66%3.66M | 39.32%698K | -39.03%945K |
| Gross profit | 36.95%1.44M | 4.62%1.27M | 45.05%4.38M | 89.45%1.06M | -2.75%1.06M | 12.18%1.05M | 178.21%1.21M | 2.34%3.02M | 12.47%559K | 10.44%1.09M |
| Operating expense | 23.84%9.27M | 8.69%8.75M | 1.15%33M | 43.52%9.84M | -18.28%7.62M | -14.09%7.49M | 4.18%8.05M | -1.87%32.62M | -32.94%6.86M | 8.49%9.32M |
| Selling and administrative expenses | 17.25%5.08M | 14.41%4.82M | 3.84%18.62M | 55.89%5.87M | -8.41%4.21M | -13.83%4.33M | -7.41%4.21M | -0.18%17.93M | -31.81%3.77M | 1.12%4.59M |
| -Selling and marketing expense | 31.90%2.97M | 15.49%2.43M | 11.63%9.45M | 74.19%2.92M | -0.77%2.18M | -5.97%2.25M | -4.41%2.11M | 10.66%8.47M | -27.31%1.67M | 8.06%2.2M |
| -General and administrative expense | 1.39%2.11M | 13.34%2.39M | -3.14%9.17M | 41.26%2.96M | -15.42%2.02M | -20.97%2.08M | -10.23%2.11M | -8.23%9.47M | -35.03%2.09M | -4.51%2.39M |
| Research and development costs | 32.90%4.19M | 2.42%3.93M | -2.13%14.38M | 28.42%3.97M | -27.85%3.42M | -14.45%3.16M | 20.75%3.84M | -3.84%14.69M | -34.26%3.09M | 16.75%4.73M |
| Operating profit | -21.71%-7.83M | -9.42%-7.48M | 3.33%-28.62M | -39.44%-8.78M | 20.33%-6.56M | 17.25%-6.44M | 6.23%-6.84M | 2.27%-29.6M | 35.26%-6.3M | -8.24%-8.23M |
| Net non-operating interest income (expenses) | 205.66%934K | 811.72%1.32M | -21.00%726K | 113.57%451K | -69.00%1.01M | -489.43%-884K | 133.87%145K | 396.45%919K | -825.91%-3.32M | 3.27M |
| Non-operating interest income | ---- | ---- | 104.48%1.64M | 139.74%1.37M | -69.00%1.01M | ---- | ---- | 291.71%803K | -3,965.17%-3.44M | 14,768.18%3.27M |
| Non-operating interest expense | ---- | ---- | 342.53%770K | ---- | ---- | ---- | ---- | 159.70%174K | ---- | ---- |
| Total other finance cost | -205.66%-934K | -811.72%-1.32M | 150.34%146K | ---- | ---- | 626.19%884K | -229.55%-145K | -164.73%-290K | ---- | ---- |
| Other net income (expenses) | -368.11%-807K | 4,200.00%301K | ||||||||
| Gain on sale of security | ---- | ---- | -128.57%-807K | ---- | ---- | ---- | ---- | 40,257.14%2.83M | ---- | ---- |
| Special income (charges) | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---2.52M | ---- | ---- |
| -Less:Impairment of capital assets | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --2.52M | ---- | ---- |
| Income before tax | 5.75%-6.9M | 7.96%-6.16M | -1.11%-28.7M | 1.96%-9.14M | -11.75%-5.55M | -23.77%-7.32M | 18.22%-6.69M | 7.23%-28.38M | 8.55%-9.32M | 16.50%-4.96M |
| Income tax | -42.86%20K | -18.75%39K | -144.60%-128K | -211.17%-229K | -47.06%18K | 118.75%35K | 54.84%48K | 173.33%287K | 764.52%206K | -34.62%34K |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 5.93%-6.92M | 8.04%-6.2M | 0.35%-28.57M | 6.49%-8.91M | -11.35%-5.56M | -24.03%-7.36M | 17.94%-6.74M | 6.61%-28.67M | 6.24%-9.53M | 16.66%-5M |
| Net income continuous operations | 5.93%-6.92M | 8.04%-6.2M | 0.35%-28.57M | 6.49%-8.91M | -11.35%-5.56M | -24.03%-7.36M | 17.94%-6.74M | 6.61%-28.67M | 6.24%-9.53M | 16.66%-5M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 5.93%-6.92M | 8.04%-6.2M | 0.35%-28.57M | 6.49%-8.91M | -11.35%-5.56M | -24.03%-7.36M | 17.94%-6.74M | 6.61%-28.67M | 6.24%-9.53M | 16.66%-5M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 5.93%-6.92M | 8.04%-6.2M | 0.35%-28.57M | 6.49%-8.91M | -11.35%-5.56M | -24.03%-7.36M | 17.94%-6.74M | 6.61%-28.67M | 6.24%-9.53M | 16.66%-5M |
| Diluted earnings per share | 20.00%-0.28 | 18.75%-0.26 | 2.17%-1.35 | 8.70%-0.42 | -8.33%-0.26 | -25.00%-0.35 | 20.00%-0.32 | 8.00%-1.38 | 6.12%-0.46 | 17.24%-0.24 |
| Basic earnings per share | 20.00%-0.28 | 18.75%-0.26 | 2.17%-1.35 | 8.70%-0.42 | -8.33%-0.26 | -25.00%-0.35 | 20.00%-0.32 | 8.00%-1.38 | 6.12%-0.46 | 17.24%-0.24 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
% Chg